Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.006
Sell
RSI(14)
40.313
Neutral
STOCH(KDJ)(9,3,3)
24.665
Neutral
ATR(14)
0.025
Low Volatility
CCI(14)
-51.245
Neutral
Williams %R
85.556
Oversold
TRIX(12,20)
-0.257
Sell
StochRSI(14)
52.877
Buy
Search
Immutep Ltd
IMMPAdd to Watchlist
0.382USD
+0.002+0.58%
Close 07-31 16:00（ET）Quotes delayed by 15 min
47.60MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+0.58%
5 Days
-0.65%
1 Month
-8.37%
6 Months
-86.01%
Year to Date
-86.64%
1 Year
-78.05%
Key Figures
0.380Open
0.405High
173.01KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
0.12%Turnover Ratio
0.380Prev. Close
0.379Low
42.16KTurnover
LossP/E Static
0.59P/B
0.00%Div Yield TTM
-34.27%ROA
3.53052wk High
1.12Volume Ratio
-61.43MNet Profit
146.04MShares
-0.0641EPS TTM
2.23Beta
-36.88%ROE
0.29352wk Low
6.82%Amplitude
100.00%Gross Margin
47.60MMarket Cap
-2.14Reward/Risk
4.62%Risk Rate
Immutep Ltd News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
2
analysts
Buy
Current Rating
5.750
Target Price
+1409.98%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Immutep Ltd
IMMP
2
Beigene Ltd
ONC
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
0.383
Sell
MA10
0.389
Sell
MA20
0.410
Sell
MA50
0.407
Sell
MA100
0.492
Sell
MA200
1.457
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Immutep Ltd Info
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.
Ticker SymbolIMMP
CompanyImmutep Ltd
CEOVoigt (Marc)
Websitehttps://www.immutep.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-2.51%
+0.32%
-1.45%
-0.92%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
-0.90%
+1.30%
-2.15%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Immutep Ltd (IMMP)?
The current price of Immutep Ltd (IMMP) is 0.39.
What is the symbol of Immutep Ltd?
The ticker symbol of Immutep Ltd is IMMP.
What is the 52-week high of Immutep Ltd?
The 52-week high of Immutep Ltd is 3.53.
What is the 52-week low of Immutep Ltd?
The 52-week low of Immutep Ltd is 0.29.
What is the market capitalization of Immutep Ltd?
The market capitalization of Immutep Ltd is 56.58M.
Is Immutep Ltd (IMMP) currently rated as Buy, Hold, or Sell?
According to analysts, Immutep Ltd (IMMP) has an overall rating of Buy, with a price target of 5.75.
What is the Earnings Per Share (EPS TTM) of Immutep Ltd (IMMP)?
The Earnings Per Share (EPS TTM) of Immutep Ltd (IMMP) is -0.28.